This is a preview of subscription content, log in via an institution to check access.
Notes
2017 euros
Reference
Holko P, et al. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist. PharmacoEconomics : 17 Apr 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0653-2
Rights and permissions
About this article
Cite this article
Vedolizumab and ustekinumab cost effective in Crohn's disease. PharmacoEcon Outcomes News 802, 34 (2018). https://doi.org/10.1007/s40274-018-4925-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4925-z